Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 38Colorectal Neoplasms 18Stomach Neoplasms 7Biliary Tract Neoplasms 5Rectal Neoplasms 3Neoplasm Metastasis 3Cholangiocarcinoma 3Neoplasms 2Metastatic Pancreatic Adenocarcinoma 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Wilms Tumor 1Weight Loss 1Triple Negative Breast Neoplasms 1Small Bowel Adenocarcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Rectal Cancer Patients 1Pseudomyxoma Peritonei 1Peritoneal Neoplasms 1Pancreatic cancer, adult 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Diseases 1Pancreatic Cancer Non-resectable 1Pancreatic Cancer Metastatic to Liver 1Pancreatic Adenocarcinoma 1PDAC - Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1

Interventions

Oxaliplatin 2Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Borderline Resectable Pancreatic Cancer × irinotecan sucrosofate × Gastrointestinal × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡